New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export NVO’s income statement to Excel — free account
Novo Nordisk A/S
NVOHealthcare Drug Manufacturers General
Novo Nordisk A/S’s revenue for fiscal 2025 (year ended December 2025) was $46.8 billion, up 11.1% from fiscal 2024.
- Revenue
- +3.87%
- EPS
- −17.1%
- Free cash flow
- −14.8%
- Total debt
- +30.7%
Quarter to September 2026, against a year earlier
38.57
0.32
−0.82%
Follow NVO
Alert me
Where the cash went Q3 FY2026, quarter to Sep 30, 2026
Free cash flow of $4.3B covered $3.1B of dividends and buybacks. Cash fell by $79.8M. What is a cash flow statement?
- Free cash flow
- $4.3B 68.3% of operating cash flow
- Returned to shareholders
- $3.1B 72.6% of free cash flow
- Debt, net
- −$911.4M repaid
- Change in cash
- −$79.8M over the period
| Operating cash flow | 6.3 |
|---|---|
| Capital expenditures | −2.0 |
| Free cash flow | 4.3 |
| Into investments, net | −0.3 |
| Dividends | −2.5 |
| Buybacks, net | −0.6 |
| Debt repaid, net | −0.9 |
| Other | −0.1 |
| Change in cash | −0.1 |
Free cash flow
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Operating cash flow | $574M | $3.8B | $8.6B | $6.3B |
| Capex | −$2.6B | −$1.8B | −$2.0B | −$2.0B |
| Free cash flow | −$2.0B | $2.0B | $6.6B | $4.3B |
Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Net Income |
2,466.68 | 3,217.33 | 7,604.03 | 3,678.48 |
+8 more quarters Free account |
Depreciation & Amortization |
2,191.14 | 1,599.77 | 553.74 | 756.70 | |
Non Cash Items (Other) |
1,453.28 | 1,848.57 | 1,747.50 | (3,314.42) | |
Change in other assets and liabilities |
236.06 | 2,105.67 | (5,203.97) | 3,757.94 | |
Other operating activities |
(50.69) | (206.46) | (929.73) | (3,538.35) | |
Operating Cash Flow |
6,296.49 | 8,564.88 | 3,771.55 | 573.80 | |
Capital expenditures |
(1,998.58) | (1,960.92) | (1,771.30) | (2,573.25) | |
Change in intangibles (net) |
(68.24) | (18.88) | (114.00) | (3,823.03) | |
Net Aquisitions |
— | — | 6.89 | 152.01 | |
Short Term Investments Change (Net) |
— | — | — | (52.45) | |
Long-Term Investments Change (Net) |
(2.19) | 0.13 | 3.29 | 3.99 | |
Other investing activities |
44.73 | 12.19 | 41.03 | — | |
Investing cash flow |
(2,286.24) | (1,974.37) | (1,834.10) | (6,292.74) | |
Repayment/Issuance of Debt (Net) |
(911.36) | (1,156.85) | 2,309.07 | 4,485.87 | |
Equity Repurchase (Common, Net) |
(622.42) | (542.04) | (375.84) | 7.22 | |
Dividends Paid (Total) |
(2,497.44) | 35.31 | (5,529.86) | 269.17 | |
Other financial activities |
(71.66) | (1,295.92) | 866.62 | — | |
Financing cash flow |
(4,102.88) | (2,959.51) | (2,730.01) | 4,762.25 | |
Exchange Rate Adjustment |
12.83 | 8.37 | (43.22) | 20.38 | |
Change in Cash |
(79.80) | 3,639.38 | (835.77) | (936.30) | |
Beginning Cash |
(42.34) | (26.46) | 4,144.26 | (81.41) | |
Ending Cash |
(122.14) | 3,612.91 | 3,308.49 | (1,017.70) | |
Dividends Paid (Common) |
(2,497.44) | 35.31 | (5,529.86) | 269.17 | |
Net Cash/Marketcap |
0.00 | 0.00 | 0.00 | 0.00 | |
Assets Liabilities Change (Total) |
236.06 | 2,105.67 | (5,203.97) | 2,991.40 | |
Investments Change (Net) |
(264.15) | 0.13 | 3.29 | (48.46) | |
Issuance/Purchase of Shares |
(622.42) | (542.04) | (375.84) | 7.22 |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026